Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
9 May 24
DEFA14A
Additional proxy soliciting materials
2 May 24
8-K
Departure of Directors or Certain Officers
2 May 24
ARS
2023 FY
Annual report to shareholders
22 Apr 24
DEF 14A
Definitive proxy
22 Apr 24
S-8
Registration of securities for employees
7 Mar 24
10-K
2023 FY
Annual report
7 Mar 24
8-K
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
7 Mar 24
8-K
Entry into a Material Definitive Agreement
26 Dec 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
13 Nov 23
8-K
ALX Oncology Announces Pricing of Public Offering
6 Oct 23
424B5
Prospectus supplement for primary offering
6 Oct 23
8-K
Results of Operations and Financial Condition
4 Oct 23
424B5
Prospectus supplement for primary offering
4 Oct 23
8-K
Other Events
4 Oct 23
EFFECT
Notice of effectiveness
11 Sep 23
424B3
Prospectus supplement
8 Sep 23
CORRESP
Correspondence with SEC
7 Sep 23
8-K
Departure of Directors or Certain Officers
6 Sep 23
UPLOAD
Letter from SEC
6 Sep 23
S-3
Shelf registration
1 Sep 23
424B5
Prospectus supplement for primary offering
25 Aug 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update
10 Aug 23
8-K
Amendments to Articles of Incorporation or Bylaws
20 Jun 23
10-Q
2023 Q1
Quarterly report
11 May 23
8-K
ALX Oncology Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
11 May 23
ARS
2022 FY
Annual report to shareholders
24 Apr 23
DEF 14A
Definitive proxy
24 Apr 23
8-K
Regulation FD Disclosure
13 Mar 23
S-8
Registration of securities for employees
9 Mar 23
10-K
2022 FY
Annual report
9 Mar 23
8-K
Results of Operations and Financial Condition
9 Mar 23
8-K
ALX Oncology Appoints Scott Garland to its Board of Directors
29 Nov 22
10-Q
2022 Q3
Quarterly report
8 Nov 22
8-K
ALX Oncology Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
8 Nov 22
8-K
ALX Oncology Enters $100 Million Loan Facility Agreement with Oxford Finance and Silicon Valley Bank to Support Ongoing Development of Evorpacept
31 Oct 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
Latest ownership filings
4
Jaume Pons
8 May 24
144
Notice of proposed sale of securities
6 May 24
4
Jaume Pons
18 Apr 24
144
Notice of proposed sale of securities
16 Apr 24
4
Jaume Pons
5 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
4
Jason Lettmann
18 Mar 24
4
Shelly Pinto
16 Feb 24
4
PETER S GARCIA
16 Feb 24
4
Sophia Randolph
16 Feb 24
4
Jaume Pons
16 Feb 24
4
Jason Lettmann
16 Feb 24
SC 13G/A
ORBIMED ADVISORS LLC
14 Feb 24
SC 13D/A
LSV Associates, LLC
14 Feb 24
SC 13G/A
Redmile Group, LLC
14 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
4
Shelly Pinto
5 Jan 24
4
Shelly Pinto
3 Jan 24
4
Sophia Randolph
3 Jan 24
4
PETER S GARCIA
3 Jan 24
4
Jaume Pons
3 Jan 24
SC 13D/A
LSV Associates, LLC
20 Dec 23
SC 13G
Redmile Group, LLC
16 Oct 23
SC 13G
Cormorant Asset Management, LP
13 Oct 23
4
Jason Lettmann
12 Sep 23
4
Sophia Randolph
27 Jul 23
4
Shelly Pinto
27 Jul 23
4
PETER S GARCIA
27 Jul 23
4
Jaume Pons
27 Jul 23
4
Shelly Pinto
7 Jul 23
4
Sophia Randolph
5 Jul 23
4
Jaume Pons
5 Jul 23
4
Shelly Pinto
5 Jul 23
4
PETER S GARCIA
5 Jul 23
4
Jack Nielsen
22 Jun 23
4
Jason Lettmann
22 Jun 23
4
Rekha Hemrajani
22 Jun 23
4
COREY S GOODMAN
22 Jun 23
4
J. Scott Garland
22 Jun 23
4
Itziar Canamasas
22 Jun 23